Literature DB >> 23355552

Aborted sudden cardiac death (SCD) in a patient with hypertrophic cardiomyopathy (HCM) with low-risk factors for SCD.

Sashank Kaushik1, Stalin Ramakrishnan Subramanian, Shahrokh Rafii, Ricardo Castillo.   

Abstract

Remarkable advancements have been made in understanding the pathophysiology of hypertrophic cardiomyopathy (HCM), since the first implantable cardioverter defibrillator (ICD) was placed in a human, more than 25 years ago to prevent sudden cardiac death (SCD). ICD has become the cornerstone in the management of HCM, with an ability to change the natural course of this complex disease. American College of Cardiology/American Heart Association guidelines have been charted out to help risk stratify asymptomatic or minimally symptomatic adults with HCM, in order to prevent SCD in such individuals. Our patient with left ventricular outflow tract gradient <30 mm Hg, left ventricular wall thickness < 30 mm, negative medical history of syncope and no family history of SCD, would have been at low risk for SCD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355552      PMCID: PMC3604283          DOI: 10.1136/bcr-2012-006459

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  J Thorac Cardiovasc Surg       Date:  2011-12       Impact factor: 5.209

Review 2.  Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy.

Authors:  Barry J Maron
Journal:  Circulation       Date:  2010-01-26       Impact factor: 29.690

3.  Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy.

Authors:  E Takagi; T Yamakado; T Nakano
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

4.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  Rory O'Hanlon; Agata Grasso; Michael Roughton; James C Moon; Susan Clark; Ricardo Wage; Jessica Webb; Meghana Kulkarni; Dana Dawson; Leena Sulaibeekh; Badri Chandrasekaran; Chiara Bucciarelli-Ducci; Ferdinando Pasquale; Martin R Cowie; William J McKenna; Mary N Sheppard; Perry M Elliott; Dudley J Pennell; Sanjay K Prasad
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

5.  Predictors of death from congestive heart failure in hypertrophic cardiomyopathy.

Authors:  H Ikeda; S Maki; N Yoshida; T Murohara; H Adachi; Y Koga; T Imaizumi
Journal:  Am J Cardiol       Date:  1999-04-15       Impact factor: 2.778

6.  Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.

Authors:  Ronen Rubinshtein; James F Glockner; Steve R Ommen; Philip A Araoz; Michael J Ackerman; Paul Sorajja; J Martijn Bos; A Jamil Tajik; Uma S Valeti; Rick A Nishimura; Bernard J Gersh
Journal:  Circ Heart Fail       Date:  2009-10-22       Impact factor: 8.790

7.  Predictors of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  S Maki; H Ikeda; A Muro; N Yoshida; A Shibata; Y Koga; T Imaizumi
Journal:  Am J Cardiol       Date:  1998-09-15       Impact factor: 2.778

Review 8.  Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.

Authors:  Barry J Maron; Martin S Maron; Christopher Semsarian
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.